Private-public alliance for the common good

Merck gets funding from GAVI to produce Ebola vaccine

Published in Microbiology

Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

A private-public deal will fund Merck&Co to produce, stockpile and attain approval for an Ebola vaccine that showed promising results last year, Nature and Science report. GAVI, a swiss organization that helps poor countries vaccinate children, announced yesterday at the World Economic Forum in Davos, Switzerland, that it will provide US $5 million to make this possible.

This vaccine is currently being used to vaccinate all known contacts of the recent Sierra Leone Ebola victim.

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in